Olanzapine Lekam

Olanzapine, the active ingredient in Olanzapine Lekam, is an atypical antipsychotic presented as an oral tablet for oral use. It is employed in the management of schizophrenia and bipolar disorder in adult patients, helping to control psychotic symptoms and mood instability.

GNH USA supplies Olanzapine Lekam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide, adhering to EU quality standards and multiple regulatory jurisdictions. The company ensures batch‑to‑batch consistency, robust cold‑chain where required, and timely delivery to global partners.

Olanzapine is an atypical antipsychotic used primarily in psychiatric disorders affecting dopamine and serotonin pathways. - Schizophrenia: reduction of acute psychotic symptoms and relapse prevention. - Bipolar I disorder (manic episodes): control of mania and rapid mood stabilization. - Maintenance treatment of bipolar disorder: prevention of recurrence of mood episodes. - Schizoaffective disorder: alleviation of both psychotic and mood symptoms.

Common Side Effects: - Weight gain: increased appetite leading to gradual weight increase. - Sedation: drowsiness or feeling of tiredness. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Dizziness: light‑headedness, especially when standing. - Increased appetite: heightened desire for food.

Serious or Rare Side Effects: - Metabolic syndrome: significant changes in glucose and lipid metabolism. - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: involuntary, repetitive movements. - Hyperglycemia: elevated blood sugar levels. - Agranulocytosis: severe reduction in white blood cells. - Seizures: occurrence of convulsive episodes.

Olanzapine requires careful monitoring due to its metabolic and neurological profile. - Monitor metabolic parameters: regular checks of weight, fasting glucose, and lipid profile. - Assess cardiovascular risk: observe blood pressure and ECG for QT changes. - Screen for movement disorders: watch for early signs of tardive dyskinesia. - Avoid abrupt discontinuation: taper the dose under medical supervision. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Olanzapine may interact with several drug classes, necessitating vigilance. Major Interactions (Avoid): - CYP1A2 inhibitors: may increase olanzapine plasma concentrations. - CNS depressants: additive sedation and respiratory depression. - Anticholinergic agents: may exacerbate cognitive impairment. Moderate Interactions (Monitor Closely): - CYP1A2 inducers: may reduce olanzapine effectiveness. - Lithium: increased risk of neurotoxicity. - Carbamazepine: may lower olanzapine plasma levels.